Uniphar Regulatory News (UPR)

AGM Statement

Dublin, London | 8 May 2025

Uniphar plc (the "Company" or "Uniphar") is holding its AGM today at 11am BST at the office of William Fry, LLP, 6th Floor, 2 Grand Canal Square, Dublin 2, D02 A342, Ireland.

At the AGM, Maurice Pratt, Chairman of Uniphar, will make the following statement:

"I am pleased to report that 2024 was another successful year for Uniphar. The Group delivered very strong organic gross profit growth of 8.2%, driven by growth across each of our three divisions. Adjusted EPS growth was 12%, free cash flow conversion was strong at 105.5% and we maintained modest leverage at 1.5x.

Our multi-year strategic capital expenditure in infrastructure and technology is progressing to plan and we now confidently expect at least 80% of our 2028 EBITDA target of €200m to be achieved through organic growth.

I am pleased to report a good start to 2025, with performance in the first four months in line with the Board's expectations. Uniphar remains well positioned to deliver organic gross profit growth across each division in line with previous guidance and to deliver on expectations for the full year.

Sustainability continues to form a key part of Uniphar's culture and business practices, and we continue to make progress across all five of our sustainability pillars.

Finally, I would like to thank our shareholders for their support. I'd also like to express my appreciation for the considerable effort and unwavering commitment from our Uniphar colleagues, management, fellow Directors and all our global teams for their loyalty, diligence, and dedication during 2024."

--- ENDS ---

Contact details

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Medtech, Uniphar Pharma and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

Uniphar solves problems for healthcare. We sit in the middle between the manufacturers and their stakeholders, and we help them both to overcome the problems of a new, complicated healthcare environment. The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare professionals and their patients. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Medtech

Uniphar Medtech is a leading pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they cannot source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.